Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hyponatremia

Vasopressin antagonists in hyponatremia: more data needed

Two new vasopressin antagonists, conivaptan and tolvaptan have recently been licensed for the treatment of hyponatremia in the USA. Their safety and clinical effectiveness seems promising, but high costs and the lack of data regarding their use in symptomatic patients call for further studies to clarify their future clinical role.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rozen-Zvi, B. et al. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am. J. Kidney Dis. 56, 325–337 (2010).

    Article  CAS  Google Scholar 

  2. Sterns, R. H., Nigwekar, S. U. & Hix, J. K. The treatment of hyponatremia. Semin. Nephrol. 29, 282–299 (2009).

    Article  CAS  Google Scholar 

  3. Velez, J. C., Dopson, S. J., Sanders, D. S., Delay, T. A. & Arthur, J. M. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol. Dial. Transplant. 25, 1524–1531 (2010).

    Article  CAS  Google Scholar 

  4. Sterns, R. H., Hix, J. K. & Silver, S. Treating profound hyponatremia: a strategy for controlled correction. Am. J. Kidney Dis. 56, 774–779 (2010).

    Article  CAS  Google Scholar 

  5. Mohmand, H. K. et al. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin. J. Am. Soc. Nephrol. 2, 1110–1117 (2007).

    Article  Google Scholar 

  6. Perianayagam, A. et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin. J. Am. Soc. Nephrol. 3, 331–336 (2008).

    Article  CAS  Google Scholar 

  7. Berl, T. et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J. Am. Soc. Nephrol. 21, 705–712 (2010).

    Article  CAS  Google Scholar 

  8. Renneboog, B. et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am. J. Med. 119, 71 e71–e78 (2006).

    Article  Google Scholar 

  9. Verbalis, J. G. et al. Hyponatremia-induced osteoporosis. J. Bone Miner. Res. 25, 554–563 (2010).

    Article  CAS  Google Scholar 

  10. Waikar, S. S., Mount, D. B. & Curhan, G. C. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am. J. Med. 122, 857–865 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard Sterns.

Ethics declarations

Competing interests

R. Sterns has received honoraria as a speaker in symposia sponsored by Astellas and Otsuka. J. Hix declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sterns, R., Hix, J. Vasopressin antagonists in hyponatremia: more data needed. Nat Rev Nephrol 7, 132–133 (2011). https://doi.org/10.1038/nrneph.2010.173

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2010.173

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing